Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and Filgrastim Post-HCT in Children With High-Risk AML
NCT07012044Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inqovi in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days, Adverse Events at 2 years and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
inqovi
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07012044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012044.